Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review
MD Sohaib Roomi, MD Waqas Ullah, MD Faizan Ahmed, MD Soban Farooq, MD Usama Sadiq, MD Asad Chohan, Munnam Jafar, MD Maryum Saddique, MD Shristi Khanal, MD Robert Watson, MD Margot Boigon
Journal of Medical Internet Research, doi:10.2196/21758
Background: During the initial phases of the COVID-19 pandemic, there was an unfounded fervor surrounding the use of hydroxychloroquine (HCQ) and tocilizumab (TCZ); however, evidence on their efficacy and safety have been controversial.
Objective: The purpose of this study is to evaluate the overall clinical effectiveness of HCQ and TCZ in patients with COVID-19. We hypothesize that HCQ and TCZ use in these patients will be associated with a reduction in in-hospital mortality, upgrade to intensive medical care, invasive mechanical ventilation, or acute renal failure needing dialysis. Methods: A retrospective cohort study was performed to determine the impact of HCQ and TCZ use on hard clinical outcomes during hospitalization. A total of 176 hospitalized patients with a confirmed COVID-19 diagnosis was included. Patients were divided into two comparison groups: (1) HCQ (n=144) vs no-HCQ (n=32) and ( 2 ) TCZ (n=32) vs no-TCZ (n=144). The mean age, baseline comorbidities, and other medications used during hospitalization were uniformly distributed among all the groups. Independent t tests and multivariate logistic regression analysis were performed to calculate mean differences and adjusted odds ratios with 95% CIs, respectively.
Results: The unadjusted odds ratio for patients upgraded to a higher level of care (ie, intensive care unit) (OR 2.6, 95% CI 1.19-5.69; P=.003) and reductions in C-reactive protein (CRP) level on day 7 of hospitalization (21% vs 56%, OR 0.21, 95% CI 0.08-0.55; P=.002) were significantly higher in the TCZ group compared to the control group. There was no significant difference in the odds of in-hospital mortality, upgrade to intensive medical care, need for invasive mechanical ventilation, acute kidney failure necessitating dialysis, or discharge from the hospital after recovery in both the HCQ and TCZ groups compared to their respective control groups. Adjusted odds ratios controlled for baseline comorbidities and medications closely followed the unadjusted estimates.
Conclusions: In this cohort of patients with COVID-19, neither HCQ nor TCZ offered a significant reduction in in-hospital mortality, upgrade to intensive medical care, invasive mechanical ventilation, or acute renal failure needing dialysis. These results are similar to the recently published preliminary results of the HCQ arm of the Recovery trial, which showed no clinical benefit from the use of HCQ in hospitalized patients with COVID-19 (the TCZ arm is ongoing). Double-blinded randomized controlled trials are needed to further evaluate the impact of these drugs in larger patient samples so that data-driven guidelines can be deduced to combat this global pandemic.
Conflicts of Interest None declared. ©Sohaib Roomi, Waqas Ullah, Faizan Ahmed, Soban Farooq, Usama Sadiq, Asad Chohan, Munnam Jafar, Maryum Saddique, Shristi Khanal, Robert Watson, Margot Boigon. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 01.09.2020. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on http://www.jmir.org/, as well as this copyright and license information must be included.
Abbreviations
References
Biot, Daher, Chavain, Fandeur, Khalife et al., Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities, J Med Chem,
doi:10.1021/jm0601856Carlucci, Ahuja, Petrilli, Rajagopalan, Jones et al., Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients, medRxiv,
doi:10.1101/2020.05.02.20080036Devaux, Rolain, Colson, Raoult, New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105938Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends,
doi:10.5582/bst.2020.01047Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, International Journal of Antimicrobial Agents,
doi:10.1016/j.ijantimicag.2020.105949Guaraldi, Meschiari, Cozzi-Lepri, Milic, Tonelli et al., Tocilizumab in patients with severe COVID-19: a retrospective cohort study, The Lancet Rheumatology,
doi:10.1016/s2665-9913(20)30173-9Horby, Landray, Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine
Ison, Wolfe, Boucher, Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process, JAMA,
doi:10.1001/jama.2020.8863Luo, Liu, Qiu, Liu, Liu et al., Tocilizumab treatment in COVID-19: A single center experience, J Med Virol,
doi:10.1002/jmv.25801Magagnoli, Narendran, Pereira, Cummings, Hardin et al., Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Retrospective Cohort Study, medRxiv,
doi:10.1016/j.medj.2020.06.001Mahevas, Tran, Roumier, Chabrol, Paule et al., No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial, medRxiv,
doi:10.1101/2020.04.10.20060699Peschken, Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic, J Rheumatol,
doi:10.3899/jrheum.200395Recovery Collaborative Group, Horby, Lim, Emberson, Mafham et al., Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report, N Engl J Med,
doi:10.1056/NEJMoa2021436Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State, JAMA,
doi:10.1001/jama.2020.8630Wilkinson, RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials, BMJ,
doi:10.1136/bmj.m1626Xu, Han, Li, Sun, Wang et al., Effective treatment of severe COVID-19 patients with tocilizumab, Proc Natl Acad Sci U S A,
doi:10.1073/pnas.2005615117Yao, Ye, Zhang, Cui, Huang et al., Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis,
doi:10.1093/cid/ciaa237Zhou, Dai, Tong, COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression, J Antimicrob Chemother,
doi:10.1093/jac/dkaa114DOI record:
{
"DOI": "10.2196/21758",
"ISSN": [
"1438-8871"
],
"URL": "http://dx.doi.org/10.2196/21758",
"abstract": "<jats:sec>\n <jats:title>Background</jats:title>\n <jats:p>During the initial phases of the COVID-19 pandemic, there was an unfounded fervor surrounding the use of hydroxychloroquine (HCQ) and tocilizumab (TCZ); however, evidence on their efficacy and safety have been controversial.</jats:p>\n </jats:sec>\n <jats:sec>\n <jats:title>Objective</jats:title>\n <jats:p>The purpose of this study is to evaluate the overall clinical effectiveness of HCQ and TCZ in patients with COVID-19. We hypothesize that HCQ and TCZ use in these patients will be associated with a reduction in in-hospital mortality, upgrade to intensive medical care, invasive mechanical ventilation, or acute renal failure needing dialysis.</jats:p>\n </jats:sec>\n <jats:sec>\n <jats:title>Methods</jats:title>\n <jats:p>A retrospective cohort study was performed to determine the impact of HCQ and TCZ use on hard clinical outcomes during hospitalization. A total of 176 hospitalized patients with a confirmed COVID-19 diagnosis was included. Patients were divided into two comparison groups: (1) HCQ (n=144) vs no-HCQ (n=32) and (2) TCZ (n=32) vs no-TCZ (n=144). The mean age, baseline comorbidities, and other medications used during hospitalization were uniformly distributed among all the groups. Independent t tests and multivariate logistic regression analysis were performed to calculate mean differences and adjusted odds ratios with 95% CIs, respectively.</jats:p>\n </jats:sec>\n <jats:sec>\n <jats:title>Results</jats:title>\n <jats:p>The unadjusted odds ratio for patients upgraded to a higher level of care (ie, intensive care unit) (OR 2.6, 95% CI 1.19-5.69; P=.003) and reductions in C-reactive protein (CRP) level on day 7 of hospitalization (21% vs 56%, OR 0.21, 95% CI 0.08-0.55; P=.002) were significantly higher in the TCZ group compared to the control group. There was no significant difference in the odds of in-hospital mortality, upgrade to intensive medical care, need for invasive mechanical ventilation, acute kidney failure necessitating dialysis, or discharge from the hospital after recovery in both the HCQ and TCZ groups compared to their respective control groups. Adjusted odds ratios controlled for baseline comorbidities and medications closely followed the unadjusted estimates.</jats:p>\n </jats:sec>\n <jats:sec>\n <jats:title>Conclusions</jats:title>\n <jats:p>In this cohort of patients with COVID-19, neither HCQ nor TCZ offered a significant reduction in in-hospital mortality, upgrade to intensive medical care, invasive mechanical ventilation, or acute renal failure needing dialysis. These results are similar to the recently published preliminary results of the HCQ arm of the Recovery trial, which showed no clinical benefit from the use of HCQ in hospitalized patients with COVID-19 (the TCZ arm is ongoing). Double-blinded randomized controlled trials are needed to further evaluate the impact of these drugs in larger patient samples so that data-driven guidelines can be deduced to combat this global pandemic.</jats:p>\n </jats:sec>",
"author": [
{
"ORCID": "http://orcid.org/0000-0001-5998-9309",
"affiliation": [],
"authenticated-orcid": false,
"family": "Roomi",
"given": "Sohaib",
"sequence": "first"
},
{
"ORCID": "http://orcid.org/0000-0002-4850-0309",
"affiliation": [],
"authenticated-orcid": false,
"family": "Ullah",
"given": "Waqas",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0003-3113-5410",
"affiliation": [],
"authenticated-orcid": false,
"family": "Ahmed",
"given": "Faizan",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-1797-9118",
"affiliation": [],
"authenticated-orcid": false,
"family": "Farooq",
"given": "Soban",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-5174-0477",
"affiliation": [],
"authenticated-orcid": false,
"family": "Sadiq",
"given": "Usama",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-1801-9792",
"affiliation": [],
"authenticated-orcid": false,
"family": "Chohan",
"given": "Asad",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-9954-1290",
"affiliation": [],
"authenticated-orcid": false,
"family": "Jafar",
"given": "Munnam",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0003-2412-7842",
"affiliation": [],
"authenticated-orcid": false,
"family": "Saddique",
"given": "Maryum",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-0443-1620",
"affiliation": [],
"authenticated-orcid": false,
"family": "Khanal",
"given": "Shristi",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0001-8500-5115",
"affiliation": [],
"authenticated-orcid": false,
"family": "Watson",
"given": "Robert",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-3531-7089",
"affiliation": [],
"authenticated-orcid": false,
"family": "Boigon",
"given": "Margot",
"sequence": "additional"
}
],
"container-title": "Journal of Medical Internet Research",
"container-title-short": "J Med Internet Res",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2020,
8,
4
]
],
"date-time": "2020-08-04T14:26:24Z",
"timestamp": 1596551184000
},
"deposited": {
"date-parts": [
[
2020,
9,
1
]
],
"date-time": "2020-09-01T14:30:41Z",
"timestamp": 1598970641000
},
"indexed": {
"date-parts": [
[
2024,
3,
3
]
],
"date-time": "2024-03-03T15:01:23Z",
"timestamp": 1709478083465
},
"is-referenced-by-count": 14,
"issue": "9",
"issued": {
"date-parts": [
[
2020,
9,
1
]
]
},
"journal-issue": {
"issue": "9",
"published-online": {
"date-parts": [
[
2020
]
]
}
},
"language": "en",
"member": "1010",
"original-title": [],
"page": "e21758",
"prefix": "10.2196",
"published": {
"date-parts": [
[
2020,
9,
1
]
]
},
"published-online": {
"date-parts": [
[
2020,
9,
1
]
]
},
"publisher": "JMIR Publications Inc.",
"reference": [
{
"DOI": "10.1056/NEJMoa2021436",
"doi-asserted-by": "publisher",
"key": "ref1"
},
{
"DOI": "10.1001/jama.2020.8863",
"doi-asserted-by": "publisher",
"key": "ref2"
},
{
"key": "ref3",
"unstructured": "HorbyPLandrayMStatement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine, 5 June 2020recoverytrial.net2020652020-06-05https://www.recoverytrial.net/files/hcq-recovery-statement-050620-final-002.pdf"
},
{
"DOI": "10.1093/jac/dkaa114",
"doi-asserted-by": "publisher",
"key": "ref4"
},
{
"DOI": "10.1016/j.ijantimicag.2020.105938",
"doi-asserted-by": "publisher",
"key": "ref5"
},
{
"DOI": "10.1093/cid/ciaa237",
"doi-asserted-by": "publisher",
"key": "ref6"
},
{
"DOI": "10.1021/jm0601856",
"doi-asserted-by": "publisher",
"key": "ref7"
},
{
"DOI": "10.1016/s0140-6736(20)30628-0",
"doi-asserted-by": "publisher",
"key": "ref8"
},
{
"DOI": "10.1073/pnas.2005615117",
"doi-asserted-by": "publisher",
"key": "ref9"
},
{
"DOI": "10.1002/jmv.25801",
"doi-asserted-by": "publisher",
"key": "ref10"
},
{
"DOI": "10.1016/s2665-9913(20)30173-9",
"doi-asserted-by": "publisher",
"key": "ref11"
},
{
"DOI": "10.1136/bmj.m1626",
"doi-asserted-by": "publisher",
"key": "ref12"
},
{
"DOI": "10.5582/bst.2020.01047",
"doi-asserted-by": "publisher",
"key": "ref13"
},
{
"DOI": "10.1016/j.ijantimicag.2020.105949",
"doi-asserted-by": "publisher",
"key": "ref14"
},
{
"DOI": "10.3899/jrheum.200395",
"doi-asserted-by": "publisher",
"key": "ref15"
},
{
"DOI": "10.1016/j.medj.2020.06.001",
"doi-asserted-by": "publisher",
"key": "ref16"
},
{
"DOI": "10.1101/2020.04.10.20060699",
"doi-asserted-by": "publisher",
"key": "ref17"
},
{
"key": "ref18",
"unstructured": "Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and HydroxychloroquineUS Food and Drug Administration20202020-06-05https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and"
},
{
"DOI": "10.1101/2020.05.02.20080036",
"doi-asserted-by": "publisher",
"key": "ref19"
},
{
"DOI": "10.1001/jama.2020.8630",
"doi-asserted-by": "publisher",
"key": "ref20"
}
],
"reference-count": 20,
"references-count": 20,
"relation": {
"has-preprint": [
{
"asserted-by": "object",
"id": "10.2196/preprints.21758",
"id-type": "doi"
}
]
},
"resource": {
"primary": {
"URL": "https://www.jmir.org/2020/9/e21758"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Health Informatics"
],
"subtitle": [],
"title": "Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review",
"type": "journal-article",
"volume": "22"
}
